US Stock MarketDetailed Quotes
VYNE VYNE Therapeutics
- 2.8900
- -0.0600-2.03%
Close Nov 26 16:00 ET
- 2.8900
- 0.00000.00%
Post 20:01 ET
42.63MMarket Cap0.85P/E (TTM)
2.9300High2.7700Low96.36KVolume2.8957Open2.9500Pre Close275.42KTurnover0.89%Turnover RatioLossP/E (Static)14.75MShares3.620052wk High0.67P/B31.21MFloat Cap1.570052wk Low--Dividend TTM10.80MShs Float2869.9200Historical High--Div YieldTTM5.42%Amplitude1.5700Historical Low2.8580Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
VYNE Therapeutics Stock Forum
Vyne Therapeutics Inc: Positive Phase 1a Sad Data for Vyn202, a Novel BD2-Selective Bet Inhibitor! well tolerated. No adverse events
Upcoming Conference Participation
•H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, New York, NY
•Stifel Immunology and Inflammation Virtual Summit, September 17-18, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
Vyne Therapeutics Announces FDA Clearance of Ind Application for Vyn202, a Novel Bd2-Selective Bet Inhibitor
NEWS
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
No comment yet